| Previous Close | 83.27 |
| Open | 83.41 |
| Bid | 82.75 x 800 |
| Ask | 83.64 x 100 |
| Day's Range | 82.86 - 84.28 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 8,473,407 |
| Avg. Volume | 9,344,542 |
| Market Cap | 109.19B |
| Beta | 0.91 |
| PE Ratio (TTM) | 9.08 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.53%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Barrons.com•15 hours ago
[$$] Getting Ready for Gilead's CAR-T
Guggenheim Securities This report includes results from our proprietary survey regarding the potential early demand for chimeric antigen receptor T-cell (CAR-T) therapy. The survey includes responses from 25 hematologists/oncologists regarding the prospective use of CAR-T therapy in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) patients. The survey had begun prior to Gilead Sciences’ (GILD) announced acquisition of Kite Pharma (KITE) on Aug. 28 of this year.
- Barrons.com•19 hours ago
Now That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?
In the fight against cancer, CAR T therapies are growing in popularity. Butler and Cha surveyed 25 hematologists/oncologists about their thoughts on potentially using CAR T therapy in appropriate patients within their practices, beginning before the Gilead-Kite Pharma deal was announced, and the results appear to be good news. From the note: Our findings suggest that the majority of surveyed hematologists/oncologists are familiar with CAR T therapy, and plan to use the therapy for either r/r ALL [relapsed and refractory acute lymphoblastic leukemia] or r/r DLBCL [diffuse large B-cell lymphoma] patients.
- Motley Fool•4 days ago
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.
